Drug Reimportation Survey Results

Pharma Marketing News is the monthly newsletter of the Pharma Marketing Network. It is distributed FREE to registered subscribers via email and the Web.

Editorial & Advisory Board

We accept advertising relevant to the interests of our subscribers.
For more information, see:

Media Kit

Published by:
VirSci Corporation
PO Box 760
Newtown, PA 18940
215-504-4164
215-504-5739 (FAX)
E-mail: infovirsci@virsci.com

Drug Reimportation Survey Results

SUMMARY

Reimportation is a growing and real concern for the pharmaceutical industry and Congress is considering several bills that seek to make drug importation from Canada legal. What's the best argument against reimportation and is new legislation required?
This article summarizes the results of a recent Pharma Marketing News Survey on this topic. The survey asked the following questions:

In your opinion, if Congress were to pass one of the 2 major reimportation bills, which bill would you prefer to be passed?
Regardless of the fate of bills in Congress, what's your level of agreement with the following arguments that have been used against reimportation of prescription drugs?

Proposed reimportation programs are too complex and expensive
FDA cannot guarantee safety of reimported drugs
Risk of endangering patients with counterfeit or substandard drugs
Would hinder the ability of pharmaceutical companies to invest in R&D for new drugs
No guarantee reimported drugs would be cheaper after middlemen get their cut

Read the full text of this article (includes tables; PDF format).

PMN38-01
Issue: Vol. 3, No. 9: October 2004
Word Count: 630
TOPICS: Strategy/Planning